Gu Yuwei, Wang Chao, Chen Shengsen, Tang Jia, Guo Xiaoxiao, Hu Wei, Cui An, Zhang Dian, Yu Kangkang, Chen Mingquan
Department of Infectious Diseases, Huashan Hospital, Shanghai, China.
Emergency Department, Huashan Hospital, Shanghai, China.
Front Genet. 2021 Mar 15;12:604461. doi: 10.3389/fgene.2021.604461. eCollection 2021.
The burden of hepatocellular carcinoma (HCC) worldwide is increasing over time, while the underlying molecular mechanism of HCC development is still under exploration. Pseudogenes are classified as a special type of long non-coding RNAs (lncRNAs), and they played a vital role in regulating tumor-associated gene expression. Here, we report that a pseudogene peptidylprolyl isomerase A pseudogene 22 (PPIAP22) and its parental gene peptidylprolyl isomerase A (PPIA) were upregulated in HCC and were associated with the clinical outcomes of HCC. Further investigation revealed that PPIAP22 might upregulate the expression of PPIA through sponging microRNA (miR)-197-3p, behaving as competing endogenous RNA (ceRNA). PPIA could participate in the development of HCC by regulating mRNA metabolic process and tumor immunity based on the functional enrichment analysis. We also found a strong correlation between the expression levels of PPIA and the immune cell infiltration or the expression of chemokines, especially macrophage, C-C motif chemokine ligand 15 (CCL15), and C-X-C motif chemokine ligand 12 (CXCL12). Our findings demonstrate that the PPIAP22/miR-197-3p/PPIA axis plays a vital role in the progression of HCC by increasing the malignancy of tumor cells and regulating the immune cell infiltration, especially macrophage, through CCL15-CCR1 or CXCL12-CXCR4/CXCR7 pathways.
随着时间的推移,全球肝细胞癌(HCC)的负担在不断增加,而HCC发生发展的潜在分子机制仍在探索之中。假基因被归类为一种特殊类型的长链非编码RNA(lncRNA),它们在调节肿瘤相关基因表达中发挥着至关重要的作用。在此,我们报告假基因肽基脯氨酰异构酶A假基因22(PPIAP22)及其亲本基因肽基脯氨酰异构酶A(PPIA)在HCC中上调,且与HCC的临床结局相关。进一步研究表明,PPIAP22可能通过海绵吸附微小RNA(miR)-197-3p上调PPIA的表达,作为竞争性内源RNA(ceRNA)发挥作用。基于功能富集分析,PPIA可通过调节mRNA代谢过程和肿瘤免疫参与HCC的发生发展。我们还发现PPIA的表达水平与免疫细胞浸润或趋化因子的表达之间存在很强的相关性,尤其是巨噬细胞、C-C基序趋化因子配体15(CCL15)和C-X-C基序趋化因子配体12(CXCL12)。我们的研究结果表明,PPIAP22/miR-197-3p/PPIA轴通过增加肿瘤细胞的恶性程度并通过CCL15-CCR1或CXCL12-CXCR4/CXCR7途径调节免疫细胞浸润,尤其是巨噬细胞浸润,在HCC进展中发挥至关重要的作用。